BRPI0922288A2 - anticorpos monoclonais anti-ferroportina 1 e seus usos. - Google Patents

anticorpos monoclonais anti-ferroportina 1 e seus usos.

Info

Publication number: BRPI0922288A2
Authority: BR; Brazil
Prior art keywords: ferroportin; monoclonal antibodies; monoclonal; antibodies
Prior art date: 2008-12-05

Application number

BRPI0922288A

Other languages

English (en)

Inventor

Ryan Witcher Derrick

Doen Mun Leung Donmienne

Vincent Manetta Joseph

Luan Peng

Tang Ying

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-05

Filing date

2009-12-01

Publication date

2018-08-28

2009-12-01 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2018-08-28 Publication of BRPI0922288A2 publication Critical patent/BRPI0922288A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0922288A 2008-12-05 2009-12-01 anticorpos monoclonais anti-ferroportina 1 e seus usos. BRPI0922288A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US12007608P	2008-12-05	2008-12-05
US23981809P	2009-09-04	2009-09-04
PCT/US2009/066187 WO2010065496A1 (en)	2008-12-05	2009-12-01	Anti-ferroportin 1 monoclonal antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
BRPI0922288A2 true BRPI0922288A2 (pt)	2018-08-28

Family

ID=41683589

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0922288A BRPI0922288A2 (pt)	2008-12-05	2009-12-01	anticorpos monoclonais anti-ferroportina 1 e seus usos.

Country Status (25)

Country	Link
EP (1)	EP2373335B1 (pt)
JP (1)	JP5713917B2 (pt)
KR (1)	KR101353117B1 (pt)
CN (1)	CN102238962B (pt)
AR (1)	AR074398A1 (pt)
AU (1)	AU2009322587B2 (pt)
BR (1)	BRPI0922288A2 (pt)
CA (1)	CA2745618C (pt)
CY (1)	CY1117355T1 (pt)
DK (1)	DK2373335T3 (pt)
EA (1)	EA020472B1 (pt)
ES (1)	ES2566343T3 (pt)
HR (1)	HRP20160302T1 (pt)
HU (1)	HUE028585T2 (pt)
IL (1)	IL212731A0 (pt)
MX (1)	MX2011005939A (pt)
NZ (1)	NZ592545A (pt)
PA (1)	PA8849601A1 (pt)
PL (1)	PL2373335T3 (pt)
SG (1)	SG171960A1 (pt)
SI (1)	SI2373335T1 (pt)
TW (1)	TW201023891A (pt)
UA (1)	UA104741C2 (pt)
WO (1)	WO2010065496A1 (pt)
ZA (1)	ZA201103941B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2871116A1 (en) *	2012-05-14	2013-11-21	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US12263205B2 (en)	2018-04-30	2025-04-01	The Children's Hospital Of Philadelphia	Methods of improving anemias by combining agents
WO2021062163A1 (en)	2019-09-27	2021-04-01	Disc Medicine, Inc.	Methods for treating myelofibrosis and related conditions
CN110806486B (zh) *	2019-11-23	2023-03-21	中南大学湘雅三医院	Mafg/as1/pcbp2/fpn1调控轴作为靶位点检测试剂的应用
WO2021231798A1 (en)	2020-05-13	2021-11-18	Disc Medicine, Inc.	Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN113980987A (zh) *	2021-12-06	2022-01-28	上海市农业科学院	一种提高植物抗镍性能的PgIREG1S和AlATP-PRTS双基因组及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7166448B1 (en) *	1999-05-10	2007-01-23	Children's Medical Center Corproation	Ferroportin1 nucleic acids and proteins
IT1319221B1 (it) *	2000-10-17	2003-09-26	Antonello Pietrangelo	Mutazioni nel gene della ferroportina 1 associata ad emocromatosiereditaria.
CA2711826C (en) *	2008-01-25	2018-02-27	Amgen Inc.	Ferroportin antibodies and methods of use

2009
- 2009-11-23 PA PA20098849601A patent/PA8849601A1/es unknown
- 2009-11-24 AR ARP090104529A patent/AR074398A1/es unknown
- 2009-11-25 TW TW098140185A patent/TW201023891A/zh unknown
- 2009-12-01 UA UAA201107028A patent/UA104741C2/uk unknown
- 2009-12-01 NZ NZ592545A patent/NZ592545A/xx not_active IP Right Cessation
- 2009-12-01 PL PL09760073T patent/PL2373335T3/pl unknown
- 2009-12-01 KR KR1020117014053A patent/KR101353117B1/ko not_active Expired - Fee Related
- 2009-12-01 JP JP2011539625A patent/JP5713917B2/ja not_active Expired - Fee Related
- 2009-12-01 EA EA201170764A patent/EA020472B1/ru not_active IP Right Cessation
- 2009-12-01 BR BRPI0922288A patent/BRPI0922288A2/pt not_active IP Right Cessation
- 2009-12-01 AU AU2009322587A patent/AU2009322587B2/en not_active Ceased
- 2009-12-01 HU HUE09760073A patent/HUE028585T2/en unknown
- 2009-12-01 ES ES09760073.8T patent/ES2566343T3/es active Active
- 2009-12-01 MX MX2011005939A patent/MX2011005939A/es active IP Right Grant
- 2009-12-01 SI SI200931382T patent/SI2373335T1/sl unknown
- 2009-12-01 SG SG2011040797A patent/SG171960A1/en unknown
- 2009-12-01 EP EP09760073.8A patent/EP2373335B1/en active Active
- 2009-12-01 CA CA2745618A patent/CA2745618C/en not_active Expired - Fee Related
- 2009-12-01 WO PCT/US2009/066187 patent/WO2010065496A1/en not_active Ceased
- 2009-12-01 CN CN200980148354.8A patent/CN102238962B/zh not_active Expired - Fee Related
- 2009-12-01 HR HRP20160302TT patent/HRP20160302T1/hr unknown
- 2009-12-01 DK DK09760073.8T patent/DK2373335T3/en active
2011
- 2011-05-05 IL IL212731A patent/IL212731A0/en unknown
- 2011-05-27 ZA ZA2011/03941A patent/ZA201103941B/en unknown
2016
- 2016-04-12 CY CY20161100296T patent/CY1117355T1/el unknown

Also Published As

Publication number	Publication date
SG171960A1 (en)	2011-07-28
CA2745618A1 (en)	2010-06-10
ES2566343T3 (es)	2016-04-12
IL212731A0 (en)	2011-07-31
ZA201103941B (en)	2012-11-28
EA020472B1 (ru)	2014-11-28
EA201170764A1 (ru)	2011-12-30
CA2745618C (en)	2014-06-10
TW201023891A (en)	2010-07-01
EP2373335B1 (en)	2016-02-24
AR074398A1 (es)	2011-01-12
NZ592545A (en)	2012-12-21
AU2009322587B2 (en)	2013-09-26
HRP20160302T1 (hr)	2016-04-22
CN102238962A (zh)	2011-11-09
PA8849601A1 (es)	2010-07-27
DK2373335T3 (en)	2016-05-02
AU2009322587A1 (en)	2011-07-28
HUE028585T2 (en)	2016-12-28
SI2373335T1 (sl)	2016-04-29
JP5713917B2 (ja)	2015-05-07
WO2010065496A1 (en)	2010-06-10
JP2012510814A (ja)	2012-05-17
PL2373335T3 (pl)	2016-08-31
KR20110084996A (ko)	2011-07-26
HK1158977A1 (zh)	2012-07-27
KR101353117B1 (ko)	2014-02-17
CN102238962B (zh)	2014-02-12
UA104741C2 (uk)	2014-03-11
EP2373335A1 (en)	2011-10-12
MX2011005939A (es)	2011-06-27
CY1117355T1 (el)	2017-04-26

Publication	Publication Date	Title
LTC2474557I2 (lt)	2021-12-10	Anti-cd79b antikūnai ir imunokonjugatai ir jų panaudojimo būdai
HUS2100038I1 (hu)	2021-10-28	Anti-CD20 antitest készítmények
BRPI0815983A2 (pt)	2018-05-22	anticorpos anti-cxcr5 humanizados, derivados dos mesmos e seus usos
CY2019004I2 (el)	2019-11-27	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0718182A2 (pt)	2014-02-25	Oligorribonucleotídeos e seus usos.
PT1920065T (pt)	2018-12-04	Anticorpos anti-alfavbeta6 e suas utilizações
BRPI0906498A2 (pt)	2015-07-14	Anticorpo ron e seus usos
DK2061814T3 (da)	2012-08-27	Antistoffer og immunokonjugater og anvendelse deraf.
BRPI0812005A2 (pt)	2019-09-24	anticorpos humanizados para o globulômeros de ab(20-42) e seus usos.
BRPI0906387A2 (pt)	2015-07-07	Anticorpos alfa 5 - beta 1 e seus usos
BRPI0807991A2 (pt)	2014-06-17	Anticorpos anti-il-23r elaborados.
BRPI0821211A2 (pt)	2015-06-16	Anticorpo anti-humano cd34 humanizado, o método de preparação e usos do mesmo.
BRPI0923231A2 (pt)	2016-01-26	anticorpo anti-cmet.
BRPI0809677A2 (pt)	2014-10-07	Anticorpos anti-ige
FI20075278A0 (fi)	2007-04-20	Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
PL3059246T3 (pl)	2018-11-30	Zmodyfikowany region stały przeciwciała
BRPI1012321A2 (pt)	2016-03-15	anticorpos anti-vegf e seus usos
HRP20150176T1 (xx)	2015-03-27	Protutijela protiv miostatina
EP2254911A4 (en)	2011-10-19	HUMANIZED ANTI-C5aR ANTIBODIES
HRP20220755T3 (hr)	2022-09-02	Anti-gm-csf antitijela i njihova uporaba
BRPI0819909A2 (pt)	2017-12-19	anticorpos antimesotelina e usos dos mesmos
NO20076607L (no)	2008-02-27	TWEAK - bindende antistoff
IL207184B (en)	2021-12-01	Cysteine engineered anti-cd79b antibodies and antibody-drug conjugates
NO344963B1 (no)	2020-08-03	Humanisert antistoff
DK1964852T3 (da)	2013-07-08	Anti-ilt7-antistof

Legal Events

Date	Code	Title	Description
2018-09-04	B15I	Others concerning applications: loss of priority
2018-09-18	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-10-30	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 8A E 9A ANUIDADES.
2019-03-19	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.